Eliglustat is an enzyme (glucosylceramide synthase) inhibitor used for the long-term treatment of type 1 Gaucherís disease in adult patients after identifying the patientís genes by an FDA-cleared test.
Eliglustat capsules are used in treating type 1 Gaucherís disease in adults.
Eliglustat should not be used :
ēIn patients who are having an allergy to eliglustat
ēIn patients who are not found suitable after getting detected by an FDA cleared test like CYP2D6 (liver enzyme) fast metabolizers. These patients may not achieve adequate concentrations of eliglustat to produce a therapeutic effect.
ēIn patients who are taking drugs which inhibit CYP3A (liver enzyme)
Eliglustat is available as 84mg capsules for treating patients with Gaucher disease type 1 based on their liver enzyme metabolism status.
If a dose of eliglustat is missed, take the prescribed dose at the next scheduled time.
The next dose should NOT be doubled.
Depending upon the liver enzyme metabolism status, eliglustat 84mg capsules are taken once or twice daily.
Swallow capsules whole by mouth, do not crush, dissolve or open the capsules.
ē Eliglustat should not be recommended in patients with a history of heart diseases like heart failure, recent heart attack, low heart rate, heart block, abnormal beats and patients using anti-arrhythmia drugs (drugs to maintain normal heartbeat).
ē Grapefruit juice intake should be avoided while taking eliglustat.
Gastrointestinal: Nausea, diarrhea, gastroesophageal reflux, dyspepsia (acidity), upper abdominal pain, constipation
Nervous system: headache, migraine
Cardiovascular: Palpitations (noticeable rapid heartbeat)
Respiratory: Oropharyngeal pain
Others: dizziness, pain in the limbs, back pain
Lab abnormalities: ECG changes should be monitored regularly.
Caution is needed while using eliglustat by pregnant women. It should be taken only if benefits are more than risks.
Pregnancy may increase the existing Gaucher disease type 1 symptoms or result in new disease manifestations. But usage of eliglustat has been found to cause reduced fetal body weight, fetal brain and skeletal abnormalities in animals.
Caution is exercised while using eliglustat by breastfeeding women.
Patients with severe kidney damage are recommended not to take eliglustat.
Eliglustat is also not recommended in all stages of liver damage.
In case of over-dosage of eliglustat, patients may experience symptoms like dizziness, disequilibrium, hypotension, low heart rate, nausea, and vomiting.
The patient should be monitored properly and given symptomatic and supportive treatment. Hemodialysis is not beneficial as eliglustat has a large volume of distribution.
Eliglustat may interact with antifungal drugs like terbinafine, ketoconazole, fluconazole, terbinafine, antacids like ranitidine and other drugs like phenytoin, and antidepressants like nortriptyline, amitriptyline, imipramine and paroxetine
Eliglustat capsules must be stored at 20 įC - 25 įC.
Subscribe to our Free Newsletters!